Moonlake Immunotherapeutics
A clinical-stage biopharmaceutical company based in Switzerland that develops immunotherapies. The grounding search tool was unavailable during this attempt, so no verified facts could be retrieved; please retry the request to obtain a properly sourced description.
Bought 5.36M
Sold 5.75M
Bought 430.0K
Granted 95.8K · Sold 534.7K
Sold 552.9K
Bought 352.1K · Sold 6.50M
Granted 450.1K · Bought 10.9K · Sold 260.9K
Sold 171.0K
Granted 23.5K · Sold 23.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chen Bihua10% owner · 35 transactions | — | 8.60Mas of Jul 2023 | — | 5.36M | — |
| Biotechnology Value Fund II LP +9 co-filersDirector, 10% owner, Director, See Explanation of Responses · 6 transactions | — | 6.60M | — | — | 5.75M |
| Helix Holdings LLCFormer 10% Holder · 2 transactions | — | 3.21Mas of Apr 2022 | — | 430.0K | — |
| Santos da Silva JorgeChief Executive Officer, Director · 18 transactions | — | 2.92M | 95.8K | — | 534.7K |
| Reich KristianChief Scientific Officer · 33 transactions | — | 2.86M | — | — | 552.9K |
| Chen Bihua +5 co-filersFormer 10% Owner · 9 transactions | — | 1.99M | — | 352.1K | 6.50M |
| Bodenstedt MatthiasChief Financial Officer · 20 transactions | — | 1.12M | 450.1K | 10.9K | 260.9K |
| Sturge SimonDirector · 3 transactions | — | 172.0Kas of Oct 2024 | — | — | 171.0K |
| Moukheibir CatherineDirector · 2 transactions | — | 23.5Kas of Jul 2025 | 23.5K | — | 23.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -7.64M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.